Ninlaro - (2.3, 3, 4 mg; Capsule, Oral)

Generic Name	Ixazomib Citrate	**Innovator**	Millenium Pharma
Dosage	2.3, 3, 4 mg; Capsule, Oral	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	Less Than 5
Other ANDA developers	Less Than 5	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.		
Complexities	Yes		

Chronology Of Events
Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary
Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status
Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition
Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events
Please Contact contact@researchdelta.com to get Detailed Information.